Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Robert J. Chilton"'
Publikováno v:
Cardiovascular Endocrinology and Metabolism ISBN: 9780323999915
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1db62c6d89310f6533777c033d611fe9
https://doi.org/10.1016/b978-0-323-99991-5.00001-2
https://doi.org/10.1016/b978-0-323-99991-5.00001-2
Autor:
Badr Harfouch, Robert J. Chilton
Publikováno v:
Cardiovascular Endocrinology and Metabolism ISBN: 9780323999915
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ef14ed309b74f763c16286512bb445b
https://doi.org/10.1016/b978-0-323-99991-5.00008-5
https://doi.org/10.1016/b978-0-323-99991-5.00008-5
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
Autor:
Alexander J. Moody, Marjorie Molina‐Wilkins, Geoffrey D. Clarke, Aurora Merovci, Carolina Solis‐Herrera, Eugenio Cersosimo, Robert J. Chilton, Patricia Iozzo, Amalia Gastaldelli, Muhammad Abdul‐Ghani, Ralph A. DeFronzo
Publikováno v:
Diabetes, obesitymetabolismREFERENCES.
To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM).Twelve patients with T2DM without clinically ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba509050b42da70db4a6166eb4aa5ed
https://pubmed.ncbi.nlm.nih.gov/36204991
https://pubmed.ncbi.nlm.nih.gov/36204991
Autor:
null Alexander J Moody, null Marjorie Molina‐Wilkins, null Geoffrey D Clarke, null Aurora Merovci, null Carolina Solis‐Herrera, null Eugenio Cersosimo, null Robert J Chilton, null Patricia Iozzo, null Amalia Gastaldelli, null Muhammad Abdul‐Ghani, null Ralph A. DeFronzo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0074731bda10b0dd2619fb8d1d8c4fe7
https://doi.org/10.1111/dom.14885/v3/response1
https://doi.org/10.1111/dom.14885/v3/response1
Autor:
Célia Bouharati, Virendra Rambiritch, Sumanth Karamchand, Robert J. Chilton, Rory Leisegang, Poobalan Naidoo, Nadina Jose
Publikováno v:
Wiener Klinische Wochenschrift
Summary Real-world evidence (RWE) is derived from real-world data (RWD) sources including electronic health records, claims data, registries (disease, product) and pragmatic clinical trials. The importance of RWE derived from RWD has been once again
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::518ae8204c1bf9cbdf038044fb8b5d70
http://europepmc.org/articles/PMC8034870
http://europepmc.org/articles/PMC8034870
Autor:
Robert J. Chilton
Publikováno v:
Diabetes, Obesity and Metabolism. 23:1215-1218
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d738ee09068bb46a73d65347de9d34
https://doi.org/10.1111/dom.14320
https://doi.org/10.1111/dom.14320
Publikováno v:
Journal of Diabetes. 13:184-190
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beae796f83aab937742812752ab84f37
https://doi.org/10.1111/1753-0407.13142
https://doi.org/10.1111/1753-0407.13142
Autor:
Célia Bouharati, Rory Forseth Leisegang, Nelusha Shunmoogam, Iftikhar O. Ebrahim, Robert J. Chilton, Frederick J. Raal, Poobalan Naidoo, Alet van Tonder, Sumanth Karamchand, Naresh Ranjith, Virendra Rambiritch, Dirk J. Blom, Moji Ganiyat Musa
Publikováno v:
Endocrine, Metabolic & Immune Disorders - Drug Targets. 20:840-854
Background: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of non-statin lipid lowering therapy that reduce LDL-cholesterol by 50 - 60%. PCSK9 inhibitors decrease LDL-cholesterol by preventing intracellular degrada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6797b376e72688bd90e5ddf0ca69f3d6
https://doi.org/10.2174/1871530320666200213114138
https://doi.org/10.2174/1871530320666200213114138
Publikováno v:
Heart Failure Reviews. 27:219-234
Recent cardiovascular outcome trials have highlighted the propensity of the antidiabetic agents, SGLT2 inhibitors (SGLT2is or -flozin drugs), to exert positive clinical outcomes in patients with cardiovascular disease at risk for major adverse cardio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b0e2af4c16ebf7c96476b55396ae473
https://doi.org/10.1007/s10741-020-09996-y
https://doi.org/10.1007/s10741-020-09996-y
Publikováno v:
Cardiovasc Endocrinol Metab
PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6f9b0f69e41d85224b3916356e9a74
https://doi.org/10.1097/xce.0000000000000204
https://doi.org/10.1097/xce.0000000000000204